- Home
- PSHG vs PRPO Comparison
PSHG vs PRPO Comparison
Compare PSHG & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- PRPO
- Stock Information
- Founded
- PSHG 2010
- PRPO N/A
- Country
- PSHG Greece
- PRPO United States
- Employees
- PSHG N/A
- PRPO N/A
- Industry
- PSHG Marine Transportation
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- PSHG Consumer Discretionary
- PRPO Industrials
- Exchange
- PSHG Nasdaq
- PRPO Nasdaq
- Market Cap
- PSHG 22.8M
- PRPO 22.0M
- IPO Year
- PSHG N/A
- PRPO N/A
- Fundamental
- Price
- PSHG $1.90
- PRPO $17.74
- Analyst Decision
- PSHG
- PRPO
- Analyst Count
- PSHG 0
- PRPO 0
- Target Price
- PSHG N/A
- PRPO N/A
- AVG Volume (30 Days)
- PSHG 108.1K
- PRPO 12.0K
- Earning Date
- PSHG 11-06-2025
- PRPO 11-05-2025
- Dividend Yield
- PSHG N/A
- PRPO N/A
- EPS Growth
- PSHG 5.84
- PRPO N/A
- EPS
- PSHG 1.56
- PRPO N/A
- Revenue
- PSHG $84,042,000.00
- PRPO $21,242,000.00
- Revenue This Year
- PSHG N/A
- PRPO N/A
- Revenue Next Year
- PSHG $17.95
- PRPO N/A
- P/E Ratio
- PSHG $1.21
- PRPO N/A
- Revenue Growth
- PSHG N/A
- PRPO 27.05
- 52 Week Low
- PSHG $1.31
- PRPO $3.90
- 52 Week High
- PSHG $2.34
- PRPO $17.78
- Technical
- Relative Strength Index (RSI)
- PSHG 53.02
- PRPO 79.98
- Support Level
- PSHG $1.76
- PRPO $14.28
- Resistance Level
- PSHG $1.95
- PRPO $16.35
- Average True Range (ATR)
- PSHG 0.11
- PRPO 0.70
- MACD
- PSHG -0.01
- PRPO 0.23
- Stochastic Oscillator
- PSHG 38.89
- PRPO 98.99
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.